#palatin technologies

Palatin Technologies, Inc. (PTN): Q2 2020 Earnings Snapshot

—  Palatin Technologies, Inc. (NYSE: PTN) reported a loss of $0.02 per share in the second quarter of 2019, vs $0.01 per share loss expected.

— Q4 revenue stood at $20,610, vs $2.54 million expected. 

— Operating expenses rose to $5.7 million from to $5.1 million a year ago mainly due to the final payment in connection with the termination of agreement on Vyleesi with Greenhill & Co.

—…

(NYSE:PTN) Palatin Technologies, Inc. Trades At Over Twice The 52 Week Low

Palatin Technologies, Inc. (NYSE:PTN)

June 22nd, 2018

Palatin Technologies, Inc. rose $0.15 Friday, a 16.14% jump, closing at $1.09. The stock continues to trade well at 203% of its 52 week low of $0.36. In addition to finishing higher, trading volumes were solid at 1,246% of normal which can indicate investors see opportunities. Be aware that the Altman Z-Score1 (An indicator of the probability…

FDA Approves ‘Female Viagra’ with Strong Warning

The first drug to treat low sexual desire in women won approval from U.S. health regulators on Tuesday, but with a warning about potentially dangerous low blood pressure and fainting side effects, especially when taken with alcohol. The U.S. Food and Drug Administration said the pink pill, to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be…

Palatin’s Bremelanotide Under Clinical Trials, Female Libido Enhancer

  Female Libido Enhancer  – Bremelanotide

Bremelanotide is a compound that is currently under investigation for its potential uses in managing reperfusion injury, female sexual dysfunction or hemorrhagic shock. The chemical may also see success in managing modulate inflammation or limiting the effects of ischemia.

N-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-trypt…